Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients

  • Fei, Zheng-Hua (The Second Clinical College, Zhejiang Chinese Medical University) ;
  • Yao, Cheng-Yun (Department of Radiotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Yang, Xiao-Lei (Department of Rehabilitation Oncology, the First Affiliated Hospital of Wenzhou Medical University) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Ma, Sheng-Lin (The Second Clinical College, Zhejiang Chinese Medical University)
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: High levels of bone morphogenetic protein (BMPs) have been reported in patients with lung cancer. This study was conducted to assess correlations between serum BMP-2 levels and prognostic outcome in patients with non-small-cell lung cancer (NSCLC). Methods: Blood samples from 84 patients with advanced NSCLC and 42 healthy controls were analyzed and quantitated for serum BMP-2 levels before and after two cycles of chemotherapy using a commercially available ELISA kit. Results: The median level of BMP-2 was 146.9 pg/ml in patients with NSCLC vs. 87.7 pg/ml in healthy controls (P<0.01). A significant correlation was observed between pretreatment serum BMP-2 level and ECOG PS, disease stage and number of organs with metastases (P<0.05). Serum BMP-2 level decreased significantly in patients who achieved objective response after two cycles of chemotherapy. Multivariate analysis showed that increased BMP-2 level and advanced clinical stage were significantly correlated with poor prognosis. Conclusion: Thes erum BMP-2 level is positively correlated with clinical stage, ECOG PS and metastatic burden and may serve as an independent negative predictor for prognosis. Decreased BMP-2 after chemotherapy could be a reliable marker for efficacy of treatment.

Keywords

References

  1. Arrieta Rodriguez OG, Villarreal-Garza C, Mart nez-Barrera L, et al (2013). Usefulness of serum carcinoembryonic antigen (cea) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: A prospective cohort study. BMC Cancer, 13, 254. https://doi.org/10.1186/1471-2407-13-254
  2. Bieniasz M, Oszajca K, Eusebio M, et al (2009). The positive correlation between gene expression of the two angiogenic factors: Vegf and bmp-2 in lung cancer patients. Lung Cancer, 66, 319-26. https://doi.org/10.1016/j.lungcan.2009.02.020
  3. Chen A, Wang D, Liu X, et al (2012). Inhibitory effect of bmp- 2 on the proliferation of breast cancer cells. Mol Med Rep, 6, 615-20. https://doi.org/10.3892/mmr.2012.962
  4. Choi YJ, Kim ST, Park KH (2012). The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients. Med Oncol, 29, 582-8. https://doi.org/10.1007/s12032-011-9852-9
  5. Dai J, Hall CL, Escara-Wilke J, et al (2008). Prostate cancer induces bone metastasis through wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res, 68, 5785-94. https://doi.org/10.1158/0008-5472.CAN-07-6541
  6. Deng H, Ravikumar TS, Yang WL (2009). Overexpression of bone morphogenetic protein 4 enhances the invasiveness of smad4-deficient human colorectal cancer cells. Cancer Lett, 281, 220-31. https://doi.org/10.1016/j.canlet.2009.02.046
  7. Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of Loubo (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7. https://doi.org/10.7314/APJCP.2013.14.1.413
  8. Dzietczenia J, Wrobel T, Jazwiec B, et al (2010). Expression of bone morphogenetic proteins (bmps) receptors in patients with b-cell chronic lymphocytic leukemia (b-cll). Int J Lab Hematol, 32, e217-21. https://doi.org/10.1111/j.1751-553X.2010.01233.x
  9. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  10. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 873-5. https://doi.org/10.7314/APJCP.2012.13.3.873
  11. Gu M, Li SY, Huang XE, et al (2013). A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. Asian Pac J Cancer Prev, 13, 5587-91. https://doi.org/10.7314/APJCP.2012.13.11.5587
  12. Hocking JC, McFarlane S (2007). Expression of bmp ligands and receptors in the developing xenopus retina. Int J Dev Biol, 51, 161-5. https://doi.org/10.1387/ijdb.062185jh
  13. Hogan BL (1996). Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev, 10, 1580-94. https://doi.org/10.1101/gad.10.13.1580
  14. Hsu PS, Wang YS, Huang SC, et al (2011). Improving detection accuracy of lung cancer serum proteomic profiling via twostage training process. Proteome Sci, 9, 20. https://doi.org/10.1186/1477-5956-9-20
  15. Hsu YL, Huang MS, Yang CJ, et al (2011). Lung tumorassociated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by runx2/snail signaling pathway. J Biol Chem, 286, 37335-46. https://doi.org/10.1074/jbc.M111.256156
  16. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-2800.
  17. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
  18. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
  19. Jones M, Dobson A, O'Brian S (2011). A graphical method for assessing agreement with the mean between multiple observers using continuous measures. Int J Epidemiol, 40, 1308-13. https://doi.org/10.1093/ije/dyr109
  20. Katsuno Y, Hanyu A, Kanda H (2008). Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through smad pathway. Oncogene, 27, 6322-33. https://doi.org/10.1038/onc.2008.232
  21. Langenfeld EM, Kong Y, Langenfeld J (2006). Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of smad-1/5. Oncogene, 25, 685-92. https://doi.org/10.1038/sj.onc.1209110
  22. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  23. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  24. Li CG, Huang XE,Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
  25. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-09.
  26. Liu C, Tian G, Tu Y, et al (2009). Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas. Jpn J Clin Oncol, 39, 625-31. https://doi.org/10.1093/jjco/hyp094
  27. Liu J, Huang XE, Tian GY, et al (2013). Phase II study on safety and efficacy of Yadanzi${\circledR}$ (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Asian Pac J Cancer Prev, 14, 2009-12. https://doi.org/10.7314/APJCP.2013.14.3.2009
  28. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  29. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
  30. Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8. https://doi.org/10.7314/APJCP.2013.14.3.2005
  31. Ma Y, Ma L, Guo Q, et al (2010). Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients. J Exp Clin Cancer Res, 29, 85. https://doi.org/10.1186/1756-9966-29-85
  32. Miyazono K (2002). A new partner for inhibitory smads. Cytokine Growth Factor Rev, 13, 7-9. https://doi.org/10.1016/S1359-6101(01)00028-4
  33. Ohe Y, Ohashi Y, Kubota K, et al (2007). Randomized phase iii study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Fourarm cooperative study in japan. Ann Oncol, 18, 317-23.
  34. Park Y, Kim JW, Kim DS, et al (2008). The bone morphogenesis protein-2 (bmp-2) is associated with progression to metastatic disease in gastric cancer. Cancer Res Treat, 40, 127-32. https://doi.org/10.4143/crt.2008.40.3.127
  35. Qian Q, Zhan P, Yu L, et al (2011). Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer. Clin Lung Cancer, 12, 131-7. https://doi.org/10.1016/j.cllc.2011.03.009
  36. Reich JM. (2005). Lung-cancer screening. N Engl J Med, 353, 2194-5. https://doi.org/10.1056/NEJM200511173532018
  37. Rothhammer T, Poser I, Soncin F, et al (2005). Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res, 65, 448-56.
  38. Shen Z, Kauttu T, Cao J, et al (2013). Macrophage coculture enhanced invasion of gastric cancer cells via tgf-beta and bmp pathways. Scand J Gastroenterol, 48, 466-72. https://doi.org/10.3109/00365521.2013.772226
  39. Shu J, Li CG, Liu YC, et al (2012).Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. Asian Pac J Cancer Prev, 13, 2399-403. https://doi.org/10.7314/APJCP.2012.13.5.2399
  40. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  41. Sun MQ, Meng AF, Huang XE, et al (2013). Comparison of psychological influence on breast cancer patients between breast-conserving surgery and modified radical mastectomy. Asian Pac J Cancer Prev, 14, 149-52. https://doi.org/10.7314/APJCP.2013.14.1.149
  42. Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22. https://doi.org/10.7314/APJCP.2013.14.3.2019
  43. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  44. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  45. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced lung adenocarcinoma cases. Asian Pac J Cancer Prev, 12, 985-7.
  46. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54. https://doi.org/10.7314/APJCP.2012.13.5.2349
  47. Xu X, Wang L, Xu HQ, Huang XE, et al (2013). Clinical comparison between paclitaxel liposome (Lipusu${\circledR}$) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4. https://doi.org/10.7314/APJCP.2013.14.4.2591
  48. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  49. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  50. Yilmaz M, Christofori G (2009). Emt, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev, 28, 15-33. https://doi.org/10.1007/s10555-008-9169-0
  51. Yin HT, Tian QZ, Guan L,n vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev, 14, 1703-6. https://doi.org/10.7314/APJCP.2013.14.3.1703
  52. Yin HT, Zhang DG, Wu XL, Huang XE, Chen G (2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev, 14, 409-12. https://doi.org/10.7314/APJCP.2013.14.1.409
  53. Yu DH, Li JH, Wang YC, et al (2011). Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for iii stage non-small cell lung cancer patients. Clin Chim Acta, 412, 930-5. https://doi.org/10.1016/j.cca.2011.01.028
  54. Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40. https://doi.org/10.7314/APJCP.2012.13.5.2339
  55. Yu Y, Yang JL, Chapman-Sheath PJ, et al (2002). Tgf-beta, bmps, and their signal transducing mediators, smads, in rat fracture healing. J Biomed Mater Res, 60, 392-7. https://doi.org/10.1002/jbm.1289
  56. Zhan YP, Huang XE, Cao J, Clinical study on safety and efficacy of Qinin (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 4773-6.
  57. Zhan YP, Huang XE, Cao J (2012). Clinical safety and efficacy of Kanglaite (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 5319-21. https://doi.org/10.7314/APJCP.2012.13.10.5319
  58. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  59. Zhang N, Ye L, Wu L, et al (2013). Expression of bone morphogenetic protein-10 (bmp10) in human urothelial cancer of the bladder and its effects on the aggressiveness of bladder cancer cells in vitro. Anticancer Res, 33, 1917-25.
  60. Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II Study on Voriconazole in Treating Chinese Patients with Malignant Hematological Disorder and Invasive Aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8. https://doi.org/10.7314/APJCP.2012.13.5.2415
  61. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.

Cited by

  1. Role of MYH Polymorphisms in Sporadic Colorectal Cancer in China: A Case-control, Population-based Study vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6403
  2. Experimental Study of Endostar Injection Concomitant with Cryoablation on Lung Adenocarcinoma A549 Xenografts vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6697
  3. New Insights into 4-Amino-2-tri-fluoromethyl-phenyl Ester Inhibition of Cell Growth and Migration in the A549 Lung Adenocarcinoma Cell Line vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7265
  4. v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2221
  5. Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3451
  6. Prognostic Value of Pretreatment Serum Alkaline Phosphatase in Nasopharyngeal Carcinoma vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3547
  7. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3581
  8. The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients vol.35, pp.11, 2014, https://doi.org/10.1007/s13277-014-2424-9
  9. Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway vol.35, pp.6, 2014, https://doi.org/10.1007/s13277-014-1673-y
  10. Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations vol.112, pp.32, 2015, https://doi.org/10.1073/pnas.1510837112
  11. A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4797
  12. Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6765
  13. Irinotecan as a Second-line Chemotherapy for Small Cell Lung Cancer: a Systemic Analysis vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1993
  14. Analysis on Early Detection of Lung Cancer by PET/CT Scan vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2215
  15. Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4013
  16. Association Between BMP-2 and Carcinogenicity vol.40, pp.23, 2015, https://doi.org/10.1097/BRS.0000000000001126
  17. Differential expression of bone morphogenetic protein 5 in human lung squamous cell carcinoma and adenocarcinoma vol.47, pp.7, 2015, https://doi.org/10.1093/abbs/gmv037
  18. BMP2 response pattern in human lung fibroblasts predicts outcome in lung adenocarcinomas vol.8, pp.1, 2015, https://doi.org/10.1186/s12920-015-0090-4
  19. Recombinant Human Bone Morphogenetic Protein-2 in Development and Progression of Oral Squamous Cell Carcinoma vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.927
  20. BMP9 inhibits the growth and migration of lung adenocarcinoma A549 cells in a bone marrow stromal cell-derived microenvironment through the MAPK/ERK and NF-κB pathways vol.36, pp.1, 2016, https://doi.org/10.3892/or.2016.4796
  21. Myostatin-like proteins regulate synaptic function and neuronal morphology vol.144, pp.13, 2017, https://doi.org/10.1242/dev.152975
  22. The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors, and fibrin architecture of a leukocyte- and platelet-rich fibrin (L-PRF) clot and membrane pp.1369-1635, 2017, https://doi.org/10.1080/09537104.2017.1293812